A global Phase 3 study of COR-003 for the treatment of endogenous Cushing's syndrome

Trial Profile

A global Phase 3 study of COR-003 for the treatment of endogenous Cushing's syndrome

Planning
Phase of Trial: Phase III

Latest Information Update: 28 Dec 2016

At a glance

  • Drugs Levoketoconazole (Primary)
  • Indications Cushing syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms LOGICS
  • Sponsors Strongbridge Biopharma
  • Most Recent Events

    • 28 Dec 2016 New trial record
    • 23 Dec 2016 According to a Strongbridge Biopharma plc media release, enrollment in this trial is anticipated to begin mid-year 2017 and top-line data are expected in Q3 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top